ARCA Biopharma (ABIO) has a novel treatment for Covid-19 in the works. The phase 2b data will be released in the 2nd quarter. In a world of wild moves in biotechnology stocks, this little biotech is trading near its lows. When this possible treatment was announced back in early 2020, ARCA Biopharma jumped to a high of $22.00. It has now settled down around $4.75/share. With new variants of Covid-19 popping up, this virus will be with the world for decades to come. Treatments are going to be extremely important. While extremely speculative, this biotech may be worth a shot for an explosive move, if the data is positive.
Members of Gareth’s Verified Investing Alerts closed out a total of 206 swing trades in 2020 for a net gain of 1,507.67%. So far in January 2021, Gareth already banked 160.44% net, just in January with members of Verified Investing Alerts. Members are crushing 2021! Join now and get the exact entry/exit price alerts, stops and targets…LIVE. Get The Action NOW by Clicking HERE